A new approach to hormone replacement therapy designed to mirror the body's own rhythm — providing steady, physiologic levels of hormone, continuously, the way nature intended.
Steady therapeutic levels, 24/7
Mirrors the body's natural delivery
Any gender, any age, any need
Patent pending, non-duplicable
Traditional hormone replacement methods deliver medication in spikes and valleys — pills, patches, injections, and pellets that introduce hormone in bursts the body never naturally experiences. Our patent-pending delivery system is engineered to do something different: provide a constant, physiologic level of hormone, continuously, in the way the human endocrine system was designed to receive it.
Hormone replacement therapy (HRT) is used to restore hormones the body no longer produces in adequate quantities — whether due to age, surgery, or endocrine disease. It is prescribed for both men and women, across a range of conditions and life stages: low testosterone, menopause, thyroid imbalance, post-surgical recovery, and more.
Illustrative — depicts the conceptual difference between peak/trough dosing and physiologic, continuous delivery.
The continuous-delivery principle behind the Nathanson platform isn't tied to a single hormone or condition. It's a delivery architecture — applicable across the most widely prescribed and most actively researched classes of hormonal and peptide therapy.
Continuous physiologic testosterone replacement for men with hypogonadism — designed to avoid the supraphysiologic peaks and sub-therapeutic troughs of weekly injection cycles.
Estrogen and combined hormone delivery for women in perimenopause and menopause — steady systemic levels engineered to address symptoms without the variability of pills, patches, or pellets.
Continuous administration of GLP-1 receptor agonists — a delivery architecture that may smooth the appetite, gastrointestinal, and tolerability profile associated with weekly injection dosing.
Investigational applications in hormone-responsive neurodegenerative conditions, where stable systemic exposure may be material to clinical outcomes.
Thyroid hormone replacement, growth and metabolic peptides, and additional indications where continuous physiologic delivery may improve upon current standards of care.
Bringing a new hormone delivery platform from concept to clinic requires laboratory work, formulation refinement, regulatory navigation, and clinical study. Contributions support research and development of a patent-pending technology that could change the standard of care for millions of patients across genders and conditions.
All contributions are directed to research and development of the Nathanson hormone delivery platform. Inquire below to learn how to support this work — at any level.
Contact for R&D SupportFor clinical inquiries, R&D support, partnership, or media — all paths begin here.